top of page
Richard M Fleming, PhD, MD, JD
DOCUMENTATION
The following diagram shows how SARS-CoV-2 is passed from person to person through respiratory droplets. Once inside the body the virus will invade our cells and reproduce itself. In response to the virus our immune system will attack the invader launching first a response from T-cells designed to kill the cells infected with the virus and later an antibody response designed to kill the virus before it gets into another cell.
This diagram also shows how too much of a good thing can cause harm to the body. When our VIRAL immune response, either because of other health problems we have (comorbidities) produce too much response OR because there is too much of the virus (e.g. vaccines) in our body; the outcome is INFLAMMATION and BLOOD CLOTTING [InflammoThrombotic Response – ITR] that can kill us (COVID-19).
The document numbers listed on the diagram below match the numbered documents providing links to the research as well as other materials not only explaining these issues but also the Gain-of-Function (GoF) research responsible for the development of this man-made virus.
.png)
SARS-CoV-2: Documents 17, 20. 144, 145, 146, 147, 148, 153, 156, 163, 164, 165, 169, 170, 182, 193, 194, 199, 209, 210, 212, 213, 214, 218, 219, 220, 221, 222, 224, 225, 233, 242, 250, 251, 253, 254, 255, 256, 263, 264, 265, 269, 280, 283, 286, 292, 296, 297, 298, 299, 301, 325, 327, 328, 330, 331, 332, 333, 334, 335, 338, 342, 343, 349, 350, 351, 353, 354, 362, 368, 375, 382, 383, 403, 405, 417, 418, 419, 425, 433, 443, 450, 473, 476, 480, 495, 499, 502, 503, 513.
Fleming InflammoThrombotic Response (ITR) Including Heart Disease, Strokes, Cancer, Diabetes Mellitus, Obesity, High Blood Pressure, & Priongenic Diseases Including Cardiac Amyloidosis: Documents 18, 19, 21, 33, 37, 49, 271, 272, 296, 297, 298, 299, 300, 302, 303, 306, 340, 341, 344, 345, 346, 361, 367, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 385, 386, 387, 388, 389, 390, 391, 392, 393, 396, 397, 398, 399, 400, 401, 402, 403, 406, 407, 417, 418, 419, 431, 432, 434, 435, 436, 437, 438, 439, 441, 442, 445, 446, 458, 478, 483, 487, 497, 500, 506, 509, 514.
Treatment Information & Immunity: Documents 40, 67, 68,
69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 151, 152, 161, 162, 168, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 183, 186, 187, 205, 206, 207, 208, 211, 216, 217, 223, 232, 235, 236, 237, 238, 239, 240, 241, 244, 245, 246, 247, 248, 249, 257, 258, 259, 260, 261, 262, 266, 267, 269, 271, 272, 276, 277, 280, 281, 285, 288, 289, 290, 291, 292, 311, 317, 319, 321, 332, 339, 348, 352, 365, 367, 369, 370, 372, 373, 379, 382, 384, 385, 386, 387, 389, 390, 391, 392, 397, 398, 402, 409, 418, 420, 422, 423, 424, 428, 429, 430, 440, 449, 480, 481, 500, 508.
Gain-of-Function (With HIV-gp120; PRRA & Prion-like Domain): Documents 7, 9, 14, 15, 16, 21, 22, 26, 35, 36, 38, 39, 41, 42, 43, 44, 45, 46, 47, 48, 50, 54, 56, 57, 160, 166, 184, 215, 226, 227, 274, 279, 282, 283, 284, 308, 309, 310, 312, 366, 409, 410, 411, 412, 413, 414, 415, 451, 456, 462, 464, 468, 469, 472, 482, 486, 487, 491, 513.
Biological Viral Weapon (Including genetic vaccines): 58, 59, 60, 61, 62, 226, 227, 243, 244, 245, 274, 279, 282, 448, 452, 453, 455, 456, 459, 460, 461, 462, 464, 465, 469, 471, 479, 484, 510, 511, 513.
Vaccines and Immunity Issues: Documents 1, 2, 3, 13, 24, 31, 32, 51, 52, 53, 55, 56, 65, 143, 149, 150, 154, 155, 158, 159, 167, 185, 188, 189, 190, 191, 192, 195, 196, 197, 198, 200, 201, 202, 203, 204, 207, 228, 229, 230, 231, 234, 268, 271, 272, 273, 275, 278, 287, 293, 294, 295, 300, 307, 313, 314, 315, 316, 318, 320, 321, 322, 329, 332, 336, 337, 339, 355, 356, 357, 358, 359, 360, 394, 395, 403, 404, 416, 426, 431, 432, 434, 435, 437, 438, 439, 441, 442, 444, 454, 463, 465, 467, 470, 474, 475, 484, 488, 489, 492, 493, 498, 509, 511, 515.
Enters Nucleus with DNA (Including CRISPR): Documents 10, 11, 12, 63, 64, 66, 157, 320, 321, 322, 324, 326, 335, 347, 447, 460, 465, 474, 475, 477, 494, 496, 501, 504, 505, 506, 507, 512, 516, 517, 518, 519, 520, 521, 522.
Antibody Dependent Enhancement of Virus: Documents 4, 5, 6, 167, 457, 466.
Neurologic - Central Nervous System - Brain: 8, 23, 25, 27, 28, 29, 30, 34, 235, 236, 238, 239, 240, 241, 248, 249, 252, 257, 270, 278, 296, 297, 298, 299, 300, 304, 305, 323, 359, 360, 361, 363, 364, 366, 367, 377, 378, 380, 391, 397, 408, 419, 421, 427, 485, 500.
1. EUA Requirements by FDA
October 2020
2. Pfizer EUA document
December 10, 2020
3. Moderna EUA Document
December 17, 2020
4. SARS-CoV-1 Antibody Dependent Enchancement (ADE)
July 5, 2011
5. ADE shown in animals including primates
January 2, 2021
7. Prion-like Domains
March 29,, 2020
8. Amyloid Precursor Proteins and Neurologic Disease
May 21, 2019
9. Amyloidosis and Prion Diseases
October 26, 2010
10. SARS-CoV-2 RT back into human DNA
December 13, 2020
15. SARS-CoV-2 Gain-of-Function Hall of Shame
October 1, 2020
16. Evidence that SARS-CoV-2 is not naturally evolved
July 1, 2020
17. South African Mutation of SARS-CoV-2
December 22, 2020
18. InflammoThrombotic Response (ITR)
August 18,2020
19. Massive Blood Clots Kill COVID Patients
August 18, 2020
20. Cryo-Electron Tomography of SARS-CoV-2 showing spike proteins
October 9, 2020
21. PRRA Superantigen increases inflammation
October 13, 2020
23. SARS-CoV-2 Spike protein crosses the blood brain barrier in mice study
December 16, 2020
24. Neurological adverse events associated with vaccines
June 2002
25. SARS-CoV-2 Invades Brain
November 30, 2020
27. Spike Protein Crosses BBB to Infect Brain
November 30, 2020
28. Fatal Invasion of Brain by SARS-CoV-2 Depends upon ACE2.
January 15, 2021
29. SARS-CoV-2 Interferes With Recognition of the Severity of Hypoxemia.
July 28, 2020
30. RNA can Behave like Prions.
July 1, 2020
33. How Immune Cells Cross the Blood-Brain Barrier.
February 4, 2019
34. Neuroinvasion, Encephalitis and Neuron Death with SARS-CoV-2.
January 19, 2021
40. Treatment of SARS-CoV-2 & COVID-19.
February 8, 2021
40. Treatment of SARS-CoV-2 & COVID-19.
February 8, 2021
41. Evidence of Gain-of-Function.
September 14, 2020
42. Gain-of-Function Hall of Shame.
October 1, 2020
43. Origins of SARS-CoV-2.
February 7, 2021
44. Genetic Structure of SARS-CoV-2.
October 16, 2020
45. Origins of SARS and PRRA.
August 12, 2020
46. The Corona Conspiracy.
October 2020
47. Probabilities of SARS-CoV-2 Origin.
November 12, 2020
48. The Fauci COVID-19 Dossier.
February 18, 2021
49. Primate studies show Inflammation in Brain & Lewy Bodies.
February 23, 2021
51. Janssen (Johnson & Johnson) EUA Document.
February 26, 2021
53. The Coxsackie & Adenovirus Receptor (CAR).
June 8, 1999
54. Deleted Wuhan Databases.
February 23, 2021
55. CDC Document on Adenovirus Vaccines.
January 8, 2020
56. COVID-19 Vaccines and Brain Injury.
April 10, 2021
57. SARS-CoV-2 Accelerates Amyloid Formation.
April 12, 2021
58. SARS-CoV-2 Is an Unrestricted Bioweapon.
Released April 24, 2021
59. SARS-CoV-2 is a Sophisticated Lab Modification.
Released April 24, 2021
60. CNN Lies and Misinformation.
September 14, 2020
61. SARS-CoV-2 - A Scientific Discussion of Lab Origin.
March 25, 2021
62. Lethal Deception.
April 22, 2021
63. Reverse Transcription of SARS-CoV-2 in Human Cells.
March 29, 2021
64. Evidence in Support of SARS-CoV-2 (Viral)-Human Cell Chimers.
March 29, 2021
65. Rethinking Vaccine Safety.
June 24, 2021
68. Italian Treatment Recommendations.
March 20, 2021
69. Commenting on Chloroquine.
March 2, 2020
70. Interleukin-6 (IL-6) levels.
April 11, 2020
71. Hydroxychloroquine (HCQ).
April 14, 2020
72. ACEI & ARBs.
May 8, 2020
73. Anti-virals.
January 27, 2020
74. Masks.
April 6, 2020
75. IL-6 Inhibitors.
May 29, 2020
76. Quantitative Nuclear Imaging of Disease.
July 24, 2019
77. Treating QTc Prolongation.
June 25, 2009
78. Hydroxychloroquine better than Chloroquine.
March 14, 2020
79. Nuclear Imaging of Infections.
January 1, 2008
80. Toll-like Receptors.
January 1, 2008
82. Mesenchymal Stem Cells.
February 18, 2020
83. TMPRSS2 and Furin Cleavage Receptors.
May 20, 2020
84. Hydroxychloroquine and Azithromycin.
April 1, 2020
85. Cuban Interferon.
March 13, 2020
86. IL-6 levels Predict Respiratory Failure.
April 1, 2020
87. Vitamin D and Steroids.
April 2020
88. Quantifying Changes in Disease & Treatment Outcomes.
January 17, 2020
89. Ivermectin Protects Nuclear Pore Complex (NPC).
March 29, 2020
90. Convalescent Plasma.
April 3, 2020
91. Multiple Drug Considerations.
May 12, 2020
92. Early Results of Convalescent Plasma.
April 13, 2020
93. N-95 Masks.
February 12, 2020
94. Face Masks in Symptomatic Individuals.
April 10, 2020
96. Lopinavir-Ritonavir Not Successful.
May 7, 2020
98. Remdesivir.
April 10, 2020
100. Multiple Treatment Considerations.
April 28, 2020
101. Rethinking ACEI and ARBS.
April 23, 2020
103. Prone Positioning of Patients Saves Lives.
June 6, 2013
104. Prone Positioning of Patients.
April 8, 2020
105. Remdesivir.
June 2020
107. SARS-CoV-2 Genome.
May 4, 2020
108. Neutralizing Antibodies.
May 18, 2020
109. Transmission of SARS-CoV-2.
April 15, 2020
112. Nebulized Antibiotics.
June 2015
113. Nebulized Antibiotics with Lung Disease.
April 1, 2016
114. Thinking About the Pharmacodynamics of Antibiotics.
Deember 12, 2011
115. Immune Response and Various Antibiotics.
December 2015
116. Azithromycin and Zika Virus.
December 13, 2016
117. Doxycycline.
May 9, 2020
118. Aminoquinolines.
April 7, 2020
119. Chloroquine Zinc Ionophore.
October 1, 2014
120. Transmembrane protease serine 2 (TMPRSS2).
April 16, 2020
121. Hydroxychloroquine - NOT alone.
April 16, 2020
122. Primaquine and Newcastle Virus.
October 1974
123. Convalescent Plasma and Viral Infections.
January 1, 2015
124. Neutralizing Antibodies.
March 15, 2020
125. Esmolol for QTc Prolongation.
March 13, 2020
126. Drugs to Avoid with Long QT Syndrome.
April 26, 2013
127. Tocilizumab.
2020
128. Tocilizumab is Effective for ITR.
April 14, 2020
129. Tocilizumab Treatment of COVID-19 Respiratory Failure.
March 27, 2020
130. Tocilizumab and Castleman Disease.
November 2008
131. Janus Kinases.
November 30, 2004
132. Interferon Combination Therapies.
May 8, 2020
134. Chloroquine Reduces Interleukins.
November 29, 2005
135. Zinc (Zn++) Ionophore.
April 9, 2020
136. Interleukin-6 (IL-6) and Steroid Resistance.
December 26, 2012
137. Inhaled Corticosteroids.
March 8, 2010
138. Inhaled Methylprednisolone.
March 30, 2020
139. Innate Immunity.
June 17, 2014
140. Clindamycin and TMPRSS2.
February 18, 2020
144. 30,091SARS-CoV-2 Nucleotide Bases.
July 14, 2021
145. The SARS-CoV-2 Virus.
June 2020
146. Recovery of Wuhan Lab Data.
June 22, 2021
147. 283 SARS-CoV-2 Case Information.
March 31, 2020
148. SARS-CoV-2-WA/CDC.
July 29, 2020
150. Pfizer UK Yellow Card Adverse Event Data.
June 30, 2021
151. Unexpected SARS-CoV-2 RNA Sequences.
May 30, 2020
152. Mask Analysis of SARS.
August 7, 2017
154. COVID-19 RNA Based Vaccines and Prion Disease.
January 18, 2021
156. Mullis PCR Patent.
July 28, 1987
158. Shedding is defined by FDA, HHS, and the Center for Biologics Evaluation and Research.
(Look at the foot notes at the bottom of page 9).
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/design-and-analysis-shedding-studies-virus-or-bacteria-based-gene-therapy-and-oncolytic-products
January 2020
163. SARS-C0V-2 Isolation Sequence & Primers.
April 12, 2020
164. Original Chinese Patients with SARS-CoV-2.
January 24, 2020
165. Appendix for # 164.
January 24, 2020
167. Patients are NOT Receiving Adequate Informed Consent.
December 4, 2020
171. Harm Caused by Excluding Family Visitation.
January 11, 2021
172. Multiple Benefits to Patients with Family Visitation.
September 15, 2020
173. Supportive Evidence for Family ICU Visitation.
November 2011
176. Let Families into Intensive Care Units (ICUs).
March 6, 2016
177. The Family Needs of Intensive Care Unit (ICU) Patients.
March 25, 2019
180. Hospital Systems Have Chosen the Fear for Us.
October 21, 2020
182. Aerosol Transmission of SARS-CoV-2?
August 7, 2020
188. Pfizer Vaccine Interferes with Tdap Vaccine.
July 25, 2021
189. SARS-CoV-1 Vaccine Leads to Lung Disease.
April 20, 2012
191. Moderna Patent - Publication
November 12, 2020
193. Beta (B.1.351) Variant Emerges in South Africa.
December 22, 2020
200. Pfizer Vaccine Shown to Reduce Innate T-Cell Response.
October 22, 2020
203. Chinese Drug Vaccine for SARS-CoV-1.
January 1, 2007
209. The Glycan Gate & The Sialic Acid Raft Receptor.
August 19, 2021
212. Baric Makes Complete Recombinant SARS Coronavirus.
October 28, 2003
216. Aloxistatin Interfers with Lysosome Fusion to Leave Cell.
August 24, 2022
218. Role of TMPRSS2 & Furin.
February17, 2021
219. Control of TMPRSS2 is Critical.
March 14, 2022
220. Urbani = SHC014.
April 5, 2021
221. Urbani Genome 2016.
July 25, 2021
222. Urbani Genome 2003.
April 21, 2003
223. E64d Reduces Amyloid.
2011 (Published February 4, 2015)
224. Rs3367 Genome.
November 22, 2013
225. MA15 Genome.
September 26, 2014
226. Origins of COVID Report.
August 2021
227. NTI Paper.
November 2021
230. Suppressed T-cell Response After Modern mRNA 1273.
July 28, 2020
231. SARS-CoV-2 Immunity from Other Viral Infections.
June 23, 2021
233. Wuhan Research Shows Asymptomatic Transmission of SARS-CoV-2.
October 27, 2020
234. LNP Effect on Innate Immunity.
August 20, 2022
235. Probucol for Treatment.
January 13, 2022
236. Aprepitant for Treatment.
February 23, 2021
237. Monoclonals for Omicron Variants.
August 30,2022
238. E64d Inhibits SARS Replication (Replicase).
October 28, 2003
239. Cathepsin B & E64d.
September 2, 2015
240. Coronavirus Synthesis Inhibited by E64d.
January 3, 1995
241. E64d Blocks Replicase Polyprotein.
February 9, 2021
243. Re-Engineered Transmissible Gastroenteritis Virus (TGEV).
August 15, 2000
244. SARS Inhibited by E64d.
July 11, 2008
245. 1st Man-made SARS; Inhibited by E64d.
October 1, 2006
246. E64d Inhibits Replicase for Numerous Viruses.
February 9, 2021
247. Regulation of Lysosomes & Autophagy by Cathepsin B.
October 27, 2016
248. E64d Protease Inhibitor.
(2007-2015)
249. APExBIO - E64d Cysteine Protease Inhibitor.
(1986-2021)
250. Spike Protein Hinge Flexibility.
July 11, 2020
252. HIV Dementia Associated with gp120& Furin Cleavage.
July 11, 2012
254. Broncho Alveolar Lavage (BAL) of SARS-CoV-2 in December 2019.
January 24, 2020
256. Wuhan Hu-1 Genome.
March 18, 2020
257. E64d and Scrapie Prion Disease.
February 15, 2000
258. Cysteine Proteases Processes Perforin.
April 6, 2010
259. Role of Cysteine in Tumor Progression.
October 3, 2013
260. E64d Ameliorates Cardiac Fibrosis.
August 2, 2008
261. Immunologic Protection from Prior Infection.
September 1, 2022
262. Supplemental Material for # 261.
September 1, 2022
263. Gastrointestinal Infection.
August 26, 2021
264. Orf6, Nup98, & Inteference with Interferon.
November 10, 2020
265. Structure SARS-CoV-2 Polymerase.
August 6, 2020
266. Airborne Transmission of Antibodies.
September 13, 2022
268. Risk-Benefit Analysis of Student Vaccination.
September 15, 2022
269. Omicron Reinfection.
September 14, 2022
270. COVID Alzheimers.
September 13, 2022
271. Lipid Nanoparticles (LNPs) Highly Inflammatory.
July 23, 2021
272. LNP Patent Litigation.
October 12, 2022
273. mRNA Patent Intellectual Property Litigation.
March 18, 2022
274. Classen Bioweapon Report.
September 20, 2022
275. Pfizer Briefing.
June 14-15, 2022
276. Prophylactic Use of Ivermectin.
August 31, 2022
277. Aminoadamantane Compounds Inhibition of Infection.
September 29, 2022
280. The Effect of Hsopital Policies for COVID.
October 2022
281. Nattokinase Effect on Spike Protein.
August 24, 2022
286. Hypothesized Origin of SARS-CoV-2.
February 6, 2020
288. Ivermectin Ineffective for Mild to Moderate Cases of COVID.
September 20, 2022
289. Ivermectin Fails in Early COVID Treatment Cases.
March 30, 2022
294. Shifts in Vaccine Benefit with Variants of Concern.
January 14, 2022
296. Amyloidogenesis of SARS-CoV-2 Spike Protein.
December 17, 2021
301. Imaging COVID-19 Pneumonia.
May 19, 2020
302. Heart Disease with COVID.
October 27, 2020
303. COVID and Heart Disease.
April 16, 2021
304. COVID & Brain Disease.
July 21, 2022
305. COVID & Amyloid Brain Disease.
January 31, 2022
306. Amyloid Disease & COVID.
November 2021
307. Omicron Vaccine Doesn't Prevent Transmission.
November 7, 2022
310. Parents Concerned About Vaccinating Their Children.
August 3, 2022
312. Synthetic Fingerprints of SARS-CoV-2.
October 20, 2022
314. Bovine (cows) Abortion, Infection and Vaccines.
October 1, 1919
315. Reinfection After Vaccination.
February 4, 2022
316. United Kingdom COVID-19 Report.
November 3, 2022
318. Vaccine Deaths (VAERS) 1997 - 2013.
May 28, 2015
319. Systematic Review of Vitamin D and COVID Severity.
November 5, 2022
322. LINE-1 Retrotransposon & Oocyte Death.
June 9, 2014
323. Alzheimer's Disease and FOXA1.
November 2021
324. LINE-1 Contributes to Genetic Change.
November 2021
325. H3K4me1.
July 20, 2022
326. Enhancer Genetics & Gene Expression.
October 20, 2022
327. Human Coronavirus NL63.
April 26, 2022
328. Human Coronavirus 229E.
July 20, 2022
331. Complete SARS-CoV-2 Genome.
April 6, 2020
333. "SARS-like" Coronaviruses and Bat Reservoir.
September 29, 2005
334. A Review of SARS-CoV-2 and Human Cells.
January 12, 2022
337. Vaccine Immunity Wanes at 4-Months.
November 14, 2022
338. Different Variants Different Symptoms.
November 11, 2022
339. Delta-Omicron (XD) & Omicron BA.1 Vaccine Antibody Immunity Escape.
November 14, 2022
342. The TRUTH About XMRV. This is NOT SARS-CoV-2!!!
October 2016
343. Electron Microscopy of SARS-CoV-2.
November 10, 2022
344. Lipid Nanoparticles (LNPs) Associated with Heart Disease.
December 17, 2021
345. COVID & Diabetes Mellitus.
January 13, 2022
346. COVID & Activation of the InflammoThrombotic Response (ITR).
January 22, 2022
347. Risks of CRISPR Gene Editing.
July 10, 2018
348. History of Immunology.
November 21, 1923
349. Computer Modeling Fails to Show Zoonotic Origin of SARS-CoV-2.
November 30, 2020
350. Pangolin NOT Source of SARS-CoV-2.
August 5, 2020
351. Dr. Fauci "It's Not Over".
December 1, 2022
352. School Masking Argument Continues.
November 9, 2022
353. A Review of SARS Virus Lab Leaks.
November 16, 2020
355. Genetic Vaccines & Shedding.
November 7, 2022
356. Aluminum Questions.
November 25, 2022
357. Aluminum in Vaccines.
August 22, 2016
358. Studying Aluminum Biodistribution.
June 17, 2015
359. Aluminum in the Brain.
November 23, 2017
360. Aluminum & Alzheimer's.
May 15, 2017
362. Variants in MERS Spike Protein.
January 2016
363. APOE, ITR & Alzheimer's.
September 24, 2022
364. ITR & Alzheimer's.
November 23, 2022
365. CRISPR & Genetic Editing.
November 23, 2022
366. Slowing Prion Disease.
November 15, 2022
367. Simvastatin & Smith-Lemli-Opitz Syndrome.
March 7, 2017
369. Drug Mechanisms of Action.
October 16, 2020
371. CD147, ITR & SARS-CoV-2 Lung Disease.
October 12, 2022
372. CD147, Azithromycin & COVID-19.
April 20, 2022
373. CD147 (EMMPRIN) Treatment of Liver Cancer.
June 11, 2012
374. BASIGIN (viz. EMMPRIN or CD147).
July 26, 2022
375. COVID Mediated Basigin & Infertility.
August 11, 2022
376. CD147 & Infertility.
February 10, 2011
377. Brain Ischemia & Hemorrhage.
August 31, 2022
378. CD147 Detrimental Neurologically.
March 19, 2020
379. Cyclophilin A Reduces Heart Damage.
June 2011
380. Matrix Proteases, ITR & Brain Inflammation.
October 2010
381. Matrix Metalloproteinases & Sperm.
May 6, 2002
382. CD147, SARS-CoV-2 & T-cells.
November 15, 2021
383. Recombinant SARS-CoV-2 Fails to Interact.
January 11, 2021
384. Imatinib Inhibits SARS-CoV-2 Infection.
April 6, 2022
385. CD147 Treatment Inhibits SARS-CoV-2.
September 25, 2021
386. Blocking CD147 Decreases Heart Disease.
January 8, 2021
387. EMMPRIN & Uterine Cancer.
March 7, 2006
389. CD147 & Liver Cancer.
June 2007
390. CD147 and Treating Liver Cancer.
September 23, 2020
391. CD147, ITR & Brain Injury.
October 11, 2017
392. CD147 and Melanoma.
February 25, 2017
393. SARS-CoV-2 Damages Lymphocytes & Lymphatic System.
April 28, 2021
394. Vaccine Efficacy Against SARS-CoV-2 Variants.
November 22, 2022
395. SARS-CoV-2; Natural versus Vaccine Immunities.
April 5, 2022
396. SARS-CoV-2 Claudin-5 Endothelial Disrution.
September 21, 2022
397. Treatment of CD147 Reduces Brain Injury.
December 2017
398. CD147 Treatment Reduces ITR.
May 8, 2008
399. Upregulating CD147 Promotes Cancer.
February 7, 2022
400. CD147 & the ITR.
September 29, 2014
401. Cyclophilins, CD147 & the ITR.
July 2005
402. Treating CD147 to Treat Cancer.
November 4, 2022
403. Post SARS-CoV-2 Infection & Vaccination Risks.
April 25, 2021
405. Characterizing SARS-CoV-2 Mutations in the U.S.A.
July 28, 2020
406. CD147 and HIV.
November 30, 2012
407. S1 Spike Subunit Induces Fibrin Clots.
August 20, 2021
408. SARS-CoV-2 Vaccines and Prion Disease.
January 2022
409. SARS-CoV-2 and Amyloidogenesis.
May 17, 2022
410. SARS-CoV-2 Gain-of-Function Lab Origin.
May 2, 2020
413. nsp14 Critical for MERS-CoV and SARS-CoV-2 Replication.
November 9, 2020
414. nsp14 and SARS-CoV-2 Mutability.
October 12, 2020
415. Investigating SARS-CoV-2.
May 12, 2022
416. Viable Attenuated SARS-CoV-2 Vaccine Includes nsp14.
November 18, 2022
417. Neu5Ac Lipid Raft Cellular Attachment.
February 13, 2008
418. Obesity, Heart Disease, Neu5Ac and the ITR - COVID Comorbidities.
September 3, 2018
419. SARS-CoV-2 and Alzheimer's.
November 23, 2022
420. Antiphospholipids and COVID-19.
August 12, 2021
422. CRISPR and Genetic Editing.
November 29, 2018
423. Genetic CRISPR Gene Editing.
August 22, 2015
424. CRISPR and Bacteriophages.
December 1, 2022
425. Infectious Agents Resilience.
January 21, 2021
426. SARS-CoV-2 Variant BW.1 Immune Escape.
November 21, 2022
427. COVID and "Brain Fog".
November 23, 2022
429. Disease Genetics.
October 2, 2014
432. InflammoThrombotic Heart Disease following COVID Vaccines.
October 6, 2022
436. CD147/ EMMERIN in Human Tumors.
October 29, 2014
437. InflammoThrombotic Diseases made worse by mRNA-lipid nanoparticles.
December 23, 2021
440. Toxilogic and Pathologic Studies of Invermectin in animal model.
February 28, 2015
445. Cardiac Amyloidosis.
January 1, 2019
446. InflammoThrombotic Response & Amyloids.
January 9, 2020
447. CRISPR Cas9 therapeutics.
January 16, 2023
448. Genetic Vaccine Products in Blood.
January 17, 2023
449. Paxlovid & Lagevrio.
January 20, 2022
450. UK Coronavirus Timeline.
January 26, 2021
451. Baric Patent for Chimeric (GoF) Coronarvirus Spike Proteins.
February 6, 2018
452. "Is COVID-19 a Bioweapon?"
February 16, 2023
453. Review by EPOCH Times.
February 16, 2023
454. mRNA sequences in blood for 28-days.
February 20, 2023
455. Merbecovirus DNA Clone Contaminating Rice.
February 20, 2023
456. Baric Gain-of-Function.
February 20, 2023
457. SARS-CoV-2 Antibody Dependent Enhancement (ADE).
February 24, 2021
458. Lung damage persists for a year in 25% of COVID patients.
February 24, 2023
460. Targeting Human Ribosomes.
February 26, 2023
461. SARS-CoV-2 Leaked From Biolab.
February 26, 2023
462. U.S. Department of Engergy - COVID-19 Lab Origins.
February 27, 2023
464. COVID Lab Origins.
February 27, 2023
467. Production of Covid-19 Vaccine Genetic Sequences.
March 5, 2021
471. 1989 Biological Weapons Anti-Terrorism Act.
March 14, 2023
473. World Health Organization.
March 16, 2020
475. Successful Reprogramming of Human Cells.
April 10, 2018
476. Optimizing Coronaviruses.
April 18, 2021
478. Treating Cardiac Amyloidosis.
April 23, 2020
480. SARS-CoV-2 & Human Immunity.
April 28, 2021
481. Zinc and Human Immunity.
April 2021
484. Increasing Delivery of Genetic Vaccines.
June 4, 2021
485. Neurologic Syringe Electronics.
June 6, 2017
486. Discussions on Origins of SARS-CoV-2.
June 18, 2021
488. Moderna Genetic Vaccine Patent.
July 7, 2020
490. CIA & Aspen Institute.
July 24, 1987
492. Lipid Nanoparticles (LNPs) for mRNA Delivery.
August 10, 2021
496. Gene Based Therapy.
August 2014
498. COVID-19 Vaccine Safety Monitoring.
September 8, 2022
499. Viral Infectivity & PCR Testing.
September 29, 2020
501. Repair Mechanisms for Damaged RNA-DNA Hybrids.
November 3, 2016
504. Increasing Genetic Vaccine Efficiency.
November 18, 2014
505. Increasing Efficacy of Genetic Vaccines and Genetic Therapy.
November 24, 2022
508. WHO Review of COVID-19 Mask Use.
December 1, 2020
509. Poly Ethylene Glycol (PEG) Antibodies Compromise PEGylated Lipid-Based Nanoparticles via InflammoThrombotic Response (ITR).
December 7, 2021
512. Coupling CRISPR with LNP Genetic Vaccines.
December 2021
516. Investigations into Preventing Cell Death.
May 20, 2019
518. Genetic Cancer Vaccines.
April 5, 2019
519. mRNA Genetic Vaccines for Cancer.
February 6, 2023
521. ACI-24; A Vaccine for Amyloid Disease.
May 16, 2022
522. Genetic Vaccine for Cystic Fibrosis.
February 6, 2023
bottom of page